AAT 076

Drug Profile

AAT 076

Alternative Names: AAT-076; RQ-00317076

Latest Information Update: 24 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator RaQualia Pharma
  • Class Analgesics
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Acute pain

Most Recent Events

  • 24 Feb 2016 Phase II development is ongoing in Japan
  • 01 Jan 2016 AAT 076 licensed to RMX Pharmaceutical Technology in China
  • 28 Dec 2011 RaQualia enters into a Letter of Intent with Chinese Academy of Sciences for licensing/co-development of RQ 00317076 for Acute pain and Lung cancer in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top